Evidence map›Paper›PMID 42460397›Full record

ArticleOpen forum infectious diseases2026

Identification of Contacts With High Rates of Missed and Asymptomatic Infection Following an Outbreak of Ebola Virus Disease: A Seroepidemiological Study in Likati Health Zone, Democratic Republic of the Congo.

Olivier Tshiani Mbaya, Koya Ariyoshi, Laura Skrip, Christian M Kahusu, Anthony Suangi, Ange Mubiala, Antoine Tshomba, Kubo Yoshinao, Gregoire Mumbere, Jean-Jacques Muyembe and 1 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olivier Tshiani MbayaDepartment of Clinical Tropical Medicine, Institute of Tropical Medicine, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.ORCID https://orcid.org/0009-0005-9050-2921
Koya AriyoshiDepartment of Global Health, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-1468-5296
Laura SkripDepartment of Global Health, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-7952-0660
Christian M KahusuDepartment of Clinical Immunology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.
Anthony SuangiDepartment of Clinical Immunology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.
Ange MubialaDepartment of Clinical Immunology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.
Antoine TshombaDepartment of Clinical Immunology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.ORCID https://orcid.org/0000-0003-2440-8468
Kubo YoshinaoDepartment of Clinical Tropical Medicine, Institute of Tropical Medicine, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Gregoire MumbereHealth Zone of Likati, Ministry of Health of the Democratic Republic of the Congo, Kinshasa, Democratic Republic of the Congo.
Jean-Jacques MuyembeDepartment of Clinical Immunology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.
Sabue MulanguDepartment of Clinical Immunology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ebola virus disease (EVD) is often regarded as severe and highly fatal, but growing evidence suggests that subclinical or minimally symptomatic infections occur and frequently go undetected. During the 2017 outbreak in Likati Health Zone, only 8 cases were confirmed despite many reported exposures. We evaluated the extent of asymptomatic or unrecognized Ebola virus infection and associated factors among contacts of reported cases. Methods: In November 2017, we conducted a cross-sectional community-based serosurvey among contacts originally identified through Ministry of Health records and newly identified through additional post-outbreak investigations. Participants provided blood samples and completed questionnaires on demographics, exposures, and symptoms within 4 weeks of symptom onset of the EVD case with whom contact was reported. Sera were tested for anti-EBOV nucleoprotein IgG by ELISA. Seropositive individuals were classified as asymptomatic (no symptoms) or unrecognized (≥1 symptom). Secondary attack rate (SAR) was estimated, and logistic regression assessed associations with sociodemographic factors, exposure level, and symptoms. Results: Among 180 participants (79 originally identified; 101 newly identified), 33 (18.3%) were seropositive. Of these, 19 (58%) reported symptoms, and 14 (42%) were asymptomatic. Any EVD-related symptom was associated with higher odds of seropositivity (OR 2.48, Conclusions: Asymptomatic infections occurred, including among contacts missed during the response, highlighting the need for exposure-based serologic assessments in EVD investigations and raising questions about immune responses and the true disease burden in outbreak-affected settings.

Indexed as

asymptomatic and paucisymptomatic infectionsDemocratic Republic of the CongoEbola virus diseaseLikatiseroepidemiology

Identifiers

PMID42460397
PMCPMC13371754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.